DarioHealth (DRIO) has disclosed a new risk, in the Litigation & Legal Liabilities category.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
DarioHealth faces significant exposure to product liability claims if its current or future digital health products are defectively designed, manufactured, or misused, or even if such defects are merely alleged. Resulting litigation could be costly, draw management attention away from operations, damage its reputation, raise insurance costs, and, if awards exceed coverage, pressure cash reserves and overall financial performance.
Overall, Wall Street has a Moderate Buy consensus rating on DRIO stock based on 1 Buy.
To learn more about DarioHealth’s risk factors, click here.